Patent
A novel strain, Lactobacillus paracasei ATG-E1 (Accession No. KCTC 14245BP), and a composition containing the same for preventing or treating respiratory diseases which are caused by fine particulate matter. The Lactobacillus paracasei ATG-E1 strain reduces the number of immune cells bronchoalveolar and lung tissues and inhibits the expression of inflammatory cytokines such as interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein 2 (MIP2), C-X-C motif chemokine ligand 1 (CXCL-1), macrophage inflammatory protein-α (MIP-1α) or interleukin-6 (IL-6). Therefore, the Lactobacillus paracasei ATG-E1 strain can be used for a treatment or health functional food for various respiratory diseases such as acute and chronic bronchitis, catarrhal bronchitis, bronchitis obliterans, inflammatory bronchitis, bronchial asthma, atopic asthma, non-atopic asthma, atopic IgE-mediated asthma, allergic asthma, non-allergic asthma, chronic bronchoconstriction, acute bronchoconstriction, chronic obstructive pulmonary disease, bronchial adenoma, pulmonary tuberculosis, emphysema, lung abscess, pulmonary fibrosis, lung cancer, airway cancer, bronchoalveolar cancer, and bronchial cancer.
1 . A method for treating a respiratory disease induced by fine particulate matter, comprising administering to a subject in need thereof Lactobacillus paracasei ATG-E1strain having the accession number of KCTC 14245BP, wherein the respiratory disease is selected from the group consisting of bronchitis, asthma, emphysema and chronic obstructive pulmonary disease (COPD).
2 . The method according to claim 1 , wherein the strain comprises a live cell thereof or a killed cell thereof.
3 . The method according to claim 1 , wherein the subject requires reducing a number of inflammatory cells and immunoregulatory cells in a bronchoalveolar or lung tissue.
4 . The method according to claim 1 , wherein the subject requires reducing expression of inflammatory cytokines including interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein 2 (MIP2), C-X-C motif chemokine ligand 1 (CXCL-1), macrophage inflammatory protein-1α (MIP-1α) or interleukin-6 (IL-6).